Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 214-881-6 | CAS number: 1205-17-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- sub-chronic toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- publication
- Title:
- In vitro penetration and subchronic toxicity of alpha-Methyl-1,3-benzodioxole-5-propionaldehyde
- Author:
- Api, A. M., Lapczynski, A., Isola, D. A., Glenn Sipes, I.
- Year:
- 2 007
- Bibliographic source:
- Food und Chemical Toxicology 45 (2007) 702 -707
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 411 (Subchronic Dermal Toxicity: 90-Day Study)
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- α-methyl-1,3-benzodioxole-5-propionaldehyde
- EC Number:
- 214-881-6
- EC Name:
- α-methyl-1,3-benzodioxole-5-propionaldehyde
- Cas Number:
- 1205-17-0
- Molecular formula:
- C11H12O3
- IUPAC Name:
- 3-(1,3-benzodioxol-5-yl)-2-methylpropanal
- Details on test material:
- - Appearance: Colourless to pale yellow clear liquid
- Stability under test conditions: Stable in acetonitrile and in the mobile phase. Protect from air
- Storage conditions of test material: At room temperature protected from light
- Handling conditions of test material: Under yellow light
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No. of test material: International, Flavors and Fragrances (Lot No. R-H120512)
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories; Portage, MI
Administration / exposure
- Type of coverage:
- semiocclusive
- Vehicle:
- water
- Remarks:
- reverse osmosis water
- Details on exposure:
- TEST SITE
- Area of exposure: dorsal area of the trunk, 5 cm²
- Time intervals for shavings or clipplings: the dorsal area of the trunk was clipped prior to administration of the first dose and then once lo twice weekly thereafter as needed.
TEST MATERIAL
- Amounts applied: 0.043-0.259 mL/kg bw/day
VEHICLE
- Amount applied: 0.259 mL/kg bw/day - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 6-7 h/day
- Frequency of treatment:
- 6 days/week (for 13 weeks)
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day
- Remarks:
- control group
- Dose / conc.:
- 50 mg/kg bw/day
- Dose / conc.:
- 150 mg/kg bw/day
- Dose / conc.:
- 300 mg/kg bw/day
- No. of animals per sex per dose:
- 15
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based on 17-day dose range finding study
- Post-exposure recovery period in satellite groups: 4 weeks
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily
DETAILED CLINICAL OBSERVATIONS: No data
DERMAL IRRITATION: Yes
- Time schedule for examinations: Daily
BODY WEIGHT: Yes
- Time schedule for examinations: Not specified
FOOD CONSUMPTION: Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No data
FOOD EFFICIENCY: No
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Not specified
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Not specified
- Anaesthetic used for blood collection: No data
- Animals fasted: No data
- How many animals: Not specified
- Parameters checked in Table 1 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Not specified
- Animals fasted: No data
- How many animals: Not specified
- Parameters checked in Table 2 were examined.
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes (see Table 3) - Other examinations:
- - organ weights
- reproductive assessment - Statistics:
- Levene’s test was performed to test for variance homogeneity. In the case of heterogeneity of variance at p ≤ 0.05, transformations were used to stabilize the variance. Comparison tests look variance heterogeneity into consideration. One-way analysis of variance (ANOVA) was used if applicable to analyze body weights, body weight changes, feed consumption, continuous clinical pathology values, and organ weight data. If the ANOVA was significant, Dunnett's t-test was used for group comparisons. Group comparisons versus control were evaluated at the 5.0%, two-tailed probability level with correction for multiple comparisons. Only data collected on or after the first day of treatment were analyzed statistically.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- Test article-related dermal irritation was observed during the treatment phase of the study at all doses ≥ 50 mg/kg/day. Findings included slight to moderate erythema, slight to moderate edema, slight to moderate desquamation, and slight, moderate, or marked atonia and fissuring. The incidences of these effects were similar across the treated groups of either sex; however, findings were generally observed at an increased incidence and severity (i.e., moderate) as the dose increases. Microscopic findings of the skin included inflammation, thickening and abnormal comification of the epidermis, epidermal ulcers and erosions. An exudate accumulated on the epidermal surface, and there was eosinophilic infiltration. Following a 4-week recovery, the skin appeared normal macroscopically and microscopically except for minimal to slight superficial dermal fibrosis in animals given ≥ 150 mg/kg/day.
- Mortality:
- no mortality observed
- Description (incidence):
- No test item-related mortalities occurred over the 13-week study or during the 4-week recovery period in rats of either sex.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Mean body weight changes and terminal body weights did not differ between treated and control groups of either sex.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Food consumption did not differ between treated and control groups of either sex.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A non-dose related increase in glucose, total protein and globulin was observed as well as a non-dose related decrease in the A/G ratio and inorganic phosphorus. These findings were typically associated with inflammation. Many of the differences were not statistically significant because of individual variability within each group. In males, statistically significant total protein and globulin levels were mildly higher only at the low and mid-doses. Lower albumin-to-globulin ratios were observed at all doses, but were statically significant only at the low and high doses- Statistically significant lower inorganic phosphorus levels were observed for males treated with 50 mg/kg bw/day. In females, the only statistically significant difference was in glucose levels, which were higher for females treated with 150 mg/kg bw/day.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Absolute and relative organ weights did not differ between treated and control groups of either sex.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Macroscopic observation of organs at necropsy detected no abnormalities.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- no effects observed
- Description (incidence and severity):
- Mean sperm count, total sperm count and sperm morphology did not differ with dose or between treated and control rats. Estrous cycles did not differ with dose or between control and test item treated rats.
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- for dermal toxicity
- Effect level:
- 50 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- dermal irritation
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- systemic toxicity
- Effect level:
- > 300 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No treatment-related systemic effects were observed.
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- The NOEL for dermal irritation was determined to be below 50 mg/kg bw/day and the NOAEL for dermal irritation was determined to be 50 mg/kg bw/Day. The NOEL as well as NOAEL for systemic toxicity was determined to be greater than 300 mg/kg bw/day.
- Executive summary:
A dermal repeated dose toxicity study was performed equivalent to OECD guideline 411 in Sprague-Dawley rats. The test item was applied dermally once daily to male and female rats (15/sex/group) at 50, 150, or 300 mg/kg bw/day (0.043, 0.129, or 0.259 mL/kg bw/day applied neat to 5 cm² dorsal skin) for at least 90 consecutive days. A control group (15/sex) was given vehicle (reverse osmosis water) at 0.259 mL/kg bw/day for a similar duration. Rats were necropsied at the end of treatment (10/sex/group) or following a 4-week recovery period (5/sex/group). The following parameters were evaluated: dermal irritation, estrous cycle, ophthalmologic examinations, body weight, feed consumption, hematology, blood coagulation, serum chemistry, organ weights, macroscopic and histopathologic examinations, and male reproductive assessment. No test item related mortalities or effects on estrous cycles, ophthalmic exams, mean body weights, mean body weight change, feed consumption, absolute or relative organ weights, macroscopic observations or male reproductive morphology/function were observed. Test item related dermal irritation was observed across all dose levels with increased incidence and severity at 300 mg/kg bw/day. Dermal irritation that initially ranged from slight to marked improved to slight (≥ 150 mg/kg bw /day) or resolved completely (50 mg/kg bw/day) during the recovery phase.
Based on the findings in this study, it can be concluded that the NOEL for dermal irritation is below 50 mg/kg bw/day and the NOAEL for dermal irritation is 50 mg/kg/bw/day when applied undiluted to 5 cm² of the dorsal skin. The NOEL as well as NOAEL for systemic toxicity is greater than 300 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.